N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development
US$4.6 million financing fully capitalizes N-Zyme Biomedical’s planned Phase 2 clinical programs in laryngopharyngeal reflux and PPI-refractory GERD, supporting the advancement of its first-in-class pepsin-targeted therapeutic approach.
N-Zyme Biomedical today announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for reflux disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721835867/en/
N-Zyme Biomedical Closes US$4.6 Million Series A Financing
